The development of effector and memory T cells in cutaneous leishmaniasis: The implications for vaccine development

Immunological Reviews

Volumn 201, Issue , 2004, Pages 318-338

  Scott, Phillip ^a,b   Artis, David ^a   Uzonna, Jude ^a   Zaph, Colby ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 12; LEISHMANIA VACCINE;

CELL MATURATION; CELL PROTECTION; CELLULAR IMMUNITY; EFFECTOR CELL; HOST SUSCEPTIBILITY; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INFECTION CONTROL; LEISHMANIA MAJOR; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; REINFECTION; REVIEW; SKIN LEISHMANIASIS; TH1 CELL;

ANIMALS; DRUG DESIGN; HUMANS; IMMUNOLOGIC MEMORY; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED STRAINS; PROTOZOAN VACCINES; TH1 CELLS;

EID: 4844220081     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00198.x     Document Type: Review

References (176)

1. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-177.
2. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002;2:845-858.
3. Scott P, Farrell JP. Experimental cutaneous leishmaniasis: induction and regulation of T cells following infection of mice with Leishmonia major. Chem Immunol 1998;70:60-80.
4. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989;169:59-72.
5. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmonia major. J Exp Med 1993;177:1505-1509.
6. Sypek JP, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993;177:1797-1802.
7. + regulatory T cells control Leishmonia major persistence and immunity. Nature 2002;420:502-507.
8. Pearson RD, Sousa AQ. Clinical spectrum of Leishmaniasis. Clin Infect Dis 1996;22:1-13.
9. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg 1986;80:859-876.
10. Weigle K, Saravia NG. Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous Leishmaniasis. Clin Dermatol 1996;14:433-450.
11. Turk JL, Bryceson AD. Immunological phenomena in leprosy and related diseases. Adv Immunol 1971;13:209-266.
12. Grimaldi G, Moriearty PL, Hoff R. Leishmania mexicana: immunology and histopathology in C3H mice. Exp Parasitol 1980;50:45-56.
13. Barral A, Petersen EA, Sacks DL, Neva FA. Late metastatic Leishmaniasis in the mouse. A model for mucocutaneous disease. Am J Trop Med Hyg 1983;32:277-285.
14. De Rossell RA, Bray RS, Alexander J. The correlation between delayed hypersensitivity, lymphocyte activation and protective immunity in experimental murine leishmaniasis. Parasite Immunol 1987;9:105-115.
15. Afonso LC, Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmonia amazonensis. Infect Immun 1993;61:2952-2959.
16. Blackwell J, Freeman J, Bradley D. Influence of H-2 complex on acquired resistance to Leishmania donovani infection in mice. Nature 1980;283:72-74.
17. + T cells. Infect Immun 1993;61:3730-3738.
18. Farrell JP, Muller I, Louis JA. A role for Lyt-2+ T cells in resistance to cutaneous leishmaniasis in immunized mice. J Immunol 1989;142:2052-2056.
19. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge wich Leishmonia major. J Immunol 2002; 168:3992-4000.
20. Scott P, Nacovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988;168:1675-1684.
21. Scott P, Caspar P, Sher A. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J Immunol 1990;144:1075-1079.
22. Reiner SL, Wang ZE, Hatam F, Scott P, Locksley RM. TH1 and TH2 cell antigen receptors in experimental leishmaniasis. Science 1993;259:1457-1460.
23. Scott P. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 1991;147:3149-3155.
24. Mougneau E, et al. Expression cloning of a protective Leishmonia antigen. Science 1995;268:563-566.
25. + T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997;6: 541-549.
26. Stetson DB, Mohrs M, Mallet-Designe V, Teyton L, Locksley RM. Rapid expansion and IL-4 expression by Leishmania-specific naive helper T cells in vivo. Immunity 2002;17:191-200.
27. Launois P, Gumy A, Himmelrich H, Locksley RM, Rocken M, Louis JA. Rapid IL-4 production by Leishmania homolog of mammalian RACK1-reactive CD4(+) T cells in resistant mice treated once with anti-IL-12 or -IFN-gamma antibodies at the onset of infection with Leishmania major instructs Th2 cell development, resulting in nonhealing lesions. J Immunol 2002;168:4628-4635.
28. Julia V, Rassoulzadegan M, Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996;274:421-423.
29. Maillard I, et al. Functional plasticity of the LACK-reactive Vbeta4-Valpha8 CD4(+) T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Eur J Immunol 2001;31:1288-1296.
30. + T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993;178:567-577.
31. Mattner F, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-1559.
32. Carrera L, et al. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 1996;183:515-526.
33. Gorak PM, Engwerda CR, Kaye PM. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 1998;28:687-695.
34. von Stebut E, Belkaid Y, Jakob T, Sacks DL, Udey MC. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmonia immunity. J Exp Med 1998;188:1547-1552.
35. Konecny P, Stagg AJ, Jebbari H, English N, Davidson RN, Knight SC. Murine dendritic cells internalize Leishmania major promastigotes, produce IL-12 p40 and stimulate primary T cell proliferation in vitro. Eur J Immunol 1999;29:1803-1811.
36. Marovich MA, McDowell MA, Thomas EK, Nutman TB. IL-12p70 production by Leishmania major-harboring human dendriuc cells is a CD40/CD40 ligand-dependent process. J Immunol 2000;164:5858-5865.
37. Quinones M, Ahuja SK, Melby PC, Pate L, Reddick RL, Ahuja SS. Preformed membrane-associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an intracellular parasite. J Exp Med 2000;192:507-516.
38. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 1995;154:5320-5330.
39. Zaph C, Scott P. Interleukin-12 regulates chemokine gene expression during the early immune response to Leishmonia major. Infect Immun 2003;71:1587-1589.
40. Beverley SM, Turco SJ. Lipophosphoglycan (LPG) and the identification of virulence genes in the protozoan parasite Leishmonia. Trends Microbiol 1998;6:35-40.
41. Hawn TR, Ozinsky A, Underbill DM, Buckner FS, Akira S, Aderem A. Leishmonia major activates IL-1 alpha expression in macrophages through a MyD88-dependent pathway. Microbes Infect 2002;4:763-771.
42. de Veer MJ, et al. MyD88 is essential for clearance of Leishmonia major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol 2003;33:2822-2831.
43. Debus A, Glasner J, Rollinghoff M, Gessner A. High levels of susceptibility and T helper 2 response in MyD88-deficient mice infected with Leishmonia major are interleukin-4 dependent. Infect Immun 2003;71:7215-7218.
44. Kropf P, et al. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmonia major. Infect Immun 2004;72:1920-1928.
45. Soong L, et al. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmonia amazonensis infection. Immunity 1996;4:263-273.
46. Kamanaka M, et al. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 1996;4:275-281.
47. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 1996;4:283-289.
48. Padigel UM, Kim N, Choi Y, Farrell JP. TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. J Immunol 2003;171:5437-5441.
49. Von Stebut E, et al. Interleukin 1 alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med 2003;198:191-199.
50. Satoskar AR, Bozza M, Rodriguez Sosa M, Lin G, David JR. Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect Immun 2001;69:906-911.
51. Wei XQ, et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 1999;163:2821-2828.
52. Monteforte GM, Takeda K, Rodriguez-Sosa M, Akira S, David JR, Satoskar AR. Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection. J Immunol 2000;164:5890-5893.
53. Xu D, et al. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol 2000;30:3147-3156.
54. Wilhelm P, et al. Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J Immunol 2001;166:4012-4019.
55. Mattner J, Schindler H, Diefenbach A, Rollinghoff M, Gresser I, Bogdan C. Regulation of type 2 nitric oxide synthase by type 1 interferons in macrophages infected with Leishmania major. Eur J Immunol 2000;30:2257-2267.
56. Pflanz S, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004;172:2225-2231.
57. Sprecher CA, et al. Cloning and characterization of a novel class I cytokine receptor. Biochem Biophys Res Commun 1998;246:82-90.
58. Chen Q, et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 2000;407:916-920.
59. Yoshida H, et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001;15:569-578.
60. Takeda A, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003;170:4886-4890.
61. Artis D, et al. Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J Immunol 2004;172:4672-4675.
62. Villarino A, et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003;19:645-655.
63. Hamano S, et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 2003;19:657-667.
64. Hondowicz BD, Scharton-Kersten TM, Jones DE, Scott P. Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do not maintain a Th2 response. J Immunol 1997;159:5024-5031.
65. Noben-Trauth N, Kropf P, Muller I. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 1996;271:987-990.
66. Kopf M, et al. IL-4-deficient Balb/c mice resist infection with Leishmania major. J Exp Med 1996;184:1127-1136.
67. Mattner F, Alber G, Magram J, Kopf M. The role of IL-12 and IL-4 in Leishmania major infection. Chem Immunol 1997;68:86-109.
68. Noben-Trauth N, Lira R, Nagase H, Paul WE, Sacks DL. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 2003;170:5152-5158.
69. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie AN. IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 2000;164:1458-1462.
70. Noben-Trauth N, Paul WE, Sacks DL. IL-4-and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J Immunol 1999;162:6132-6140.
71. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001;166:1141-1147.
72. Groux H, et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol 1999;162:1723-1729.
73. Hagenbaugh A, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997;185:2101-2110.
74. Kima PE, et al. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J Exp Med 2000;191:1063-1068.
75. von Stebut E, Belkaid Y, Nguyen BV, Gushing M, Sacks DL, Udey MC. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis. Eur J Immunol 2000;30:3498-3506.
76. + T cell polarization in mice is modulated by strain-specific major histocompatibility complex-independent differences within dendritic cells. J Exp Med 2003;198:201-209.
77. Jones D, Elloso MM, Showe L, Williams D, Trinchieri G, Scott P. Differential regulation of the interleukin-12 receptor during the Innate immune response to Leihsmania major. Infect Immun 1998;66:3818-3824.
78. + T cells resulting in a state of unresponsiveness to IL-12. J Immunol 1998;161:6156-6163.
79. Szabo SJ, Jacobson NG, Dighe AS, Gubler U, Murphy KM. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 1995;2:665-675.
80. Guler ML, et al. Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development. Science 1996;271:984-987.
81. Mullen AC, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001;292:1907-1910.
82. Nabors GS, Afonso LC, Farrell JP, Scott P. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc Natl Acad Sci USA 1995;92:3142-3146.
83. Lighvani AA, et al. T-bet is rapidly induced by interferon-garnma in lymphoid and myeloid cells. Proc Natl Acad Sci USA 2001;98:15137-15142.
84. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002;2:933-944.
85. Nishikomori R, Gurunathan S, Nishikomori K, Strober W. BALB/c mice bearing a transgenic IL-12 receptor beta 2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling. J Immunol 2001;166:6776-6783.
86. Li J, Hunter CA, Farrell JP. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol 1999;162:974-979.
87. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 2002;195:1499-1505.
88. Farrell JP, Kirkpatrick CE. Experimental cutaneous leishmaniasis. II. A possible role for prostaglandins in exacerbation of disease in Leishmania major-infected BALB/c mice. J Immunol 1987;138:902-907.
89. Park AY, Hondowicz B, Kopf M, Scott P. The role of IL-12 in maintaining resistance to Leishmania major. J Immunol 2002;168:5771-5777.
90. Beebe AM, Mauze S, Schork NJ, Coffman RL. Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice. Immunity 1997;6:551-557.
91. + T cells. J Exp Med 1995;182:1591-1596.
92. + T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med 1995;182:1579-1584.
93. Boonstra A, et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 2003;197:101-109.
94. Parish CR. Immune response to chemically modified flagellin. II. Evidence for a fundamental relationship between humoral and cell-mediated immunity. J Exp Med 1971;134:21-47.
95. Bretscher PA, Wei G, Menon JN, Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 1992;257:539-542.
96. + T cells. J Exp Med 2004;199:1559-1566.
97. Thomas MJ, Noble A, Sawicka E, Askenase PW, Kemeny DM. CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation. J Immunol 2002;168:216-223.
98. Kim JJ, et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 1998;102:1112-1124.
99. + T cells are a biologically relevant source of macrophage inflammatory protein-1 alpha in vivo. J Immunol 1999;162:5423-5428.
100. + T cells. J Immunol 2000;165:915-924.
101. Muller I. Role of T cell subsets during the recall of immunologic memory to Leishmania major. Eur J Immunol 1992;22:3063-3069.
102. Herath S, Kropf P, Muller I. Cross-talk between CD8(+) and CD4(+) T cells in experimental cutaneous leishmaniasis: CD8(+) T cells are required for optimal IFN-gamma production by CD4(+) T cells. Parasite Immunol 2003;25:559-567.
103. Gurunathan S, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997;186:1137-1147.
104. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
105. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000;18:621-663.
106. Speirs K, Caamano J, Goldschmidt MH, Hunter CA, Scott P. NF-kappa B2 is required for optimal CD40-induced IL-12 production but dispensable for Th 1 cell differentiation. J Immunol 2002;168:4406-4413.
107. + Th1 cell development and resistance to Leishmania major. J Immunol 2003;170:1995-2003.
108. Feuillard J, Korner M, Israel A, Vassy J, Raphael M. Differential nuclear localization of p50, p52, and RelB proteins in human accessory cells of the immune response in situ. Eur J Immunol 1996;26:2547-2551.
109. Grigoriadis G, et al. The Rel subunit of NF-kappaB-like transcription factors is a positive and negative regulator of macrophage gene expression: distinct roles for Rel in different macrophage populations. EMBO J 1996;15:7099-7107.
110. Artis D, et al. Differential requirement for NF-kappa B family members in control of helminth infection and intestinal inflammation. J Immunol 2002;169:4481-4487.
111. Das J, Chen CH, Yang L, Cohn L, Ray P, Ray A. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2001;2:45-50.
112. Medzhitov R, CpG DNA: security code for host defense. Nat Immunol 2001;2:15-16.
113. Rhee EG, et al. Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 2002;195:1565-1573.
114. Khalil EA, et al. Autoclaved Leishmonia major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000;356:1565-1569.
115. Sharifi I, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998;351:1540-1543.
116. Park AY, Hondowicz BD, Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol 2000;165:896-902.
117. Stobie L, et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci USA 2000;97:8427-8432.
118. Constantinescu CS, Hondowicz BD, Elloso MM, Wysocka M, Trinchieri G, Scott P. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur J Immunol 1998;28:2227-2233.
119. Oppmann B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-725.
120. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
121. Murphy EE, et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994;180:223-231.
122. Dubey C, Croft M, Swain SL. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J Immunol 1996;157:3280-3289.
123. + T cells from human immunodeficiency virus-infected persons. J Exp Med 1995;182:1759-1767.
124. Marth T, Zeitz M, Ludviksson BR, Strober W, Kelsall BL. Extinction of IL-12 signaling promotes Fas-mediated apoptosis of antigen-specific T cells. J Immunol 1999;162:7233-7240.
125. Palmer EM, Farrokh-Siar L, Maguire van Seventer J, van Seventer GA. IL-12 decreases activation-induced cell death in human naive Th cells costimulated by intercellular adhesion molecule-1. I. IL-12 alters caspase processing and inhibits enzyme function. J Immunol 2001;167:749-758.
126. + T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol 2002;169:3637-3643.
127. Chang J, Cho JH, Lee SW, Choi SY, Ha SJ, Sung YC. IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells. J Immunol 2004;172:2818-2826.
128. Zhang X, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997;185:1837-1849.
129. + T cells in vivo by IL-15. Immunity 1998;8:591-599.
130. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988;140:4245-42S2.
131. Wenner CA, Guler ML, Macatonia SE, O'Garra A, Murphy KM. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol 1996;156:1442-1447.
132. Mocci S, Coffman RL. Induction of a Th2 population from a polarized Leishmonia-specific Th1 population by in vitro culture with IL-4. J Immunol 1995;154:3779-3787.
133. Mocci S, Coffman RL, The mechanism of in vitro T helper cell type 1 to T helper cell type 2 switching in highly polarized Leishmonia major-specific T cell populations. J Immunol 1997;158:1559-1564.
134. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001;410:101-105.
135. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-712.
136. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001;291:2413-2417.
137. Roman E, et al. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med 2002;196:957-968.
138. + effector and memory T cell generation. Nat Immunol 2003;4:835-842.
139. Wherry EJ, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-234.
140. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmonia major. Science 1994;263:235-237.
141. Gurunathan S, Prussia C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998;4:1409-1415.
142. Uzonna JE, Wei G, Yurkowski D, Bretscher P. Immune elimination of Leishmonia major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 2001;167:6967-6974.
143. Belkaid Y, et al. The role of interleukin (IL)-10 in the persistence of Leishmonia major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001;194:1497-1506.
144. Zinkernagel RM. On natural and artificial vaccinations. Annu Rev Immunol 2003;21:515-546.
145. Gray D. A role for antigen in the maintenance of immunological memory. Nat Rev Immunol 2002;2:60-65.
146. Swain SL, Hu H, Huston G. Class II-independent generation of CD4 memory T cells from effectors. Science 1999;286:1381-1383.
147. Murali-Kriskna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 1999;286:1377-1381.
148. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002;111:837-851.
149. Iezzi G, Scheidegger D, Lanzavecchia A. Migration and function of antigen-primed nonpolarized T lymphocytes in vivo. J Exp Med 2001;193:987-993.
150. Wang X, Mosmann T. In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or IFN-gamma-secreting cells. J Exp Med 2001;194:1069-1080.
151. Doyle AM, et al. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J Exp Med 2001;194:893-902.
152. Fearon DT, Manders P, Wagner SD. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science 2001;293:248-250.
153. Hayashi N, Liu D, Min B, Ben-Sasson SZ, Paul WE. Antigen challenge leads to in vivo activation and elimination of highly polarized TH1 memory T cells. Proc Natl Acad Sci USA 2002;99:6187-6191.
154. Wu CY, et al. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol 2002;3:852-858.
155. Harbertson J, Biederman E, Bennett KE, Kondrack RM, Bradley LM. Withdrawal of stimulation may initiate the transition of effector to memory CD4 cells. J Immunol 2002;168:1095-1102.
156. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 1995;92:10267-10271.
157. Yap G, Pesin M, Sher A. Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplosma gondii. J Immunol 2000;165:628-631.
158. Melby PC. Vaccination against cutaneous leishmaniasis: current status. Am J Clin Dermatol 2002;3:557-570.
159. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001;14:229-243.
160. Manetti R, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177:1199-1204.
161. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-549.
162. + T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993;90:10188-10192.
163. Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modabber F, Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001;69:245-251.
164. Mitchell GF, Handman E, Spithill TW. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust J Exp Biol Med Sci 1984;62:145-153.
165. Mitchell GF, Handman E. Leishmonia tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility. Aust J Exp Biol Med Sci 1983;61:11-25.
166. Spath GF, et al. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmonia major. Proc Natl Acad Sci USA 2000;97:9258-9263.
167. Alexander J, Coombs GH, Mottram JC. Leishmonia mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998;161:6794-6801.
168. Huang C, Turco SJ. Defective galactofuranose addition in lipophosphoglycan biosynthesis in a mutant of Leishmonia donovani. J Biol Chem 1993;268:24060-24066.
169. Ryan KA, Garraway IA, Descoteaux A, Turco SJ, Beverley SM. Isolation of virulence genes directing surface glycosylphosphatidylinositol synthesis by functional complementation of Leishmania. Proc Natl Acad Sci USA 1993;90:8609-8613.
170. Spath GF, Lye LF, Segawa H, Sacks DL, Turco SJ, Beverley SM. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 2003;301:1241-1243.
171. Ma D, Russell DG, Beverley SM, Turco SJ. Golgi GDP-mannose uptake requires Leishmonia LPG2. A member of a eukaryotic family of putative nudeotide-sugar transporters. J Biol Chem 1997;272:3799-3805.
172. Descoteaux A, Luo Y, Turco SJ, Beverley SM. A specialized pathway affecting virulence glycoconjugates of Leishmonia. Science 1995;269:1869-1872.
173. Uzonna JE, Spath GF, Beverley SM, Scott P. Vaccination with phosphoglycan-deficient Leishmonia major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 2004;172:3793-3797.
174. Mendez S, et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect Immun 2003;71:5121-5129.
175. Ramirez-Pineda JR, Frohlich A, Berberich C, Moll H. Dendritic Cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 2004;172:6281-6289.
176. Reed SG, Campos-Neto A. Vaccines for parasitic and bacterial diseases. Curr Opin Immunol 2003;15:456-460.